Skip to main content
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Keyword
Specialties
Allergy & Immunology
Autoimmune
CardioVascular
Clinical Pathways
Dentistry
Dermatology
Emergency & Mobile Medicine
Endocrinology & Diabetes
Gastroenterology
Infectious Diseases
Neurology
Obstetrics & Gynecology
Oncology
Ophthalmology
Pediatrics
Podiatry
Population Health
Psychiatry & Behavioral Health
Pulmonology
Rheumatology & Arthritis
Surgery
Urology
Wound Care
Events
Education
About
Sign In
Search
Haresh Jhangiani
The PI3K Inhibitor ME-401 ± Rituximab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL), Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Purpose of the Study: ME-401, a potent and selective oral PI3k inhibitor, is being evaluated in a Phase 1b study in patients (pts) with R/R B-cell malignancies (NCT02914938). 101 pts were...
Jamie Wood ;
Adam Asch ;
Igor Gorbatchevsky ;
John Pagel ;
Andrew Zelenetz ;
Nishitha Reddy ;
Deepa Jagadeesh ;
Anastasios Stathis ;
Huda Salman ;
Jacob Soumerai ;
Vaishalee Kenkre ;
Haresh Jhangiani ;
Judith Llorin-Sangalang ;
10/22/2019
Featured CME Course
Targeted Therapies for the Management of Chronic Lymphocytic Leukemia: Evaluating the Evidence to Optimize Patient Care and Outcomes
Upcoming Events
February 2 – February 5
February 7 – February 9
February 27 – March 1
March 17 – March 19
March 22 – March 23
March 27 – March 30
March 31 – April 2
April 21 – April 24
April 30 – May 4
May 1 – May 3
See Full Calendar